Welcome to ADC London
Maximising the Clinical Therapeutic Window of Antibody-drug Conjugates
Now in its 11th year, World ADC London prides itself in being the industry-leading conference to help forward thinking researchers from the pharmaceutical, biotech and academic community advance the development of antibody-drug conjugates.
Bringing together the latest ADC science, clinical data and lessons learned to enable drug developers to maximise the clinical therapeutic window of your ADC.
Get together with over 300 experts across 140+ active organisations as they unite at this industry focussed conference and foster new connections, develop business relationships and meet with current partners.
Join us in 2021 at Europe’s longest standing and most comprehensive ADC conference to power the development of your ADC pipeline.
“World ADC conferences from Hanson Wade are a key part of the ADC ecosystem, contributing to the growth of knowledge, ideas, and community network.”
"A great place to meet peers and partners, learn about novel ADC approaches and better understand the direction, the field is headed for."
“Excellent talks by all the speakers with a transparent and frank attitude to share good and bad experiences gained in the challenging world of ADCs in oncology. A deep and valuable analysis of the state of the art of ADCs with a focus on solid tumors potential.”
- Menarini Ricerche
About World ADC Series
The World ADC team ploughs its collective energy into sourcing the insights you need. We investigate the most challenging problems facing the industry; source the leading experts who have game-changing solutions; and distill this into accessible formats of information exchange – for you. From globally leading conferences, to webinars and industry reports, whatever the information you need, World ADC can offer you the insights you need to accelerate your ADC programs.
The value World ADC provides you is the power of insight and connections. Not artificial, and not short-lived. We nurture the right environments in which people can communicate problems and solutions; share novel data and forge networks across the industry that will make each of your endeavors more informed and more robust.
We share a common belief with the industry – that the potential of antibody drug conjugates is enormous. In the war against cancer, ADCs can be a game-changer and we know that the right insights and connections can sharpen the weapons that are in your arsenal.
Join us at the heart of the ADC community to improve your programs and be part of the mission to develop better antibody drug conjugate drugs.